Despite the efficacy of these group of HSP27 inhibitors, there are still some toxicity related issues with some having poor efficacy hence, the need to discover, develop or design more compounds that can interfere with HSP27-mediated resistance in cancer. Here, HSPB1 is linked to cancer.